Medicina Fluminensis, Vol. 61 No. 1, 2025.
Pregledni rad
https://doi.org/10.21860/medflum2025_323581
Targeted Therapy for the Treatment of Metastatic Non-Small-Cell Lung Cancer with ALK Gene Rearrangement
Melany Ćurić
orcid.org/0000-0002-7817-9405
; Klinički bolnički centar Rijeka, Zavod za pulmologiju, Rijeka, Hrvatska
*
Vuk Prica
; Klinički bolnički centar Rijeka, Zavod za pulmologiju, Rijeka, Hrvatska
* Dopisni autor.
Sažetak
Non-small cell lung cancer is represented in 85% of the total number of lung cancers. With the progress of diagnostics, certain mutations have been proven, since an individualized approach to the treatment of lung cancer is being developed. One of these mutations, present in 3-7% of patients, is the anaplastic lymphoma kinase (ALK) mutation. Three generations of drugs are used in the treatment of advanced ALK positive non-small cell lung cancer. Crizotinib belongs to the first generation, alectinib, ceritinib and brigatinib to the second generation, and lorlatinib belongs to the third generation. All of them are superior to traditional chemotherapy treatment. The most superior of all is lorlatinib, which belongs to the third-generation group, because it is still sensitive to resistant mutations and best penetrates the blood-brain barrier. The aim of this review article is to compare the effectiveness, safety, mechanisms of action and side effects of the mentioned drugs.
Ključne riječi
anaplastic lymphoma kinase; lung neoplasms; tyrosine kinase inhibitors
Hrčak ID:
323581
URI
Datum izdavanja:
1.3.2025.
Posjeta: 274 *